地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：15172431432
传真：13212737804
邮箱：sales@amyjet.com
Swant专注于钙结合蛋白相关产品的研发和销售，产品包括：钙结合蛋白抗体、纯化的重组蛋白、钙离子通道和钙泵抗体以及其他抗体和ELISA。
Antibodies to Calbindin D-28k, Calretinin, Parvalbumin, Calmodulin and to Na2+-Ca2+-exchangers, Ca2+ pumps, neurotransmitters, as well as their respective antigens. Superb staining of subpopulation of neurons or glial cells in various species, including humans. Selective staining of various types of cancers. Our mono- and polyclonal antibodies are of high titer and of high specificity. They can be used in immunohistochemistry and immunoblots at dilution of more than 1:5'000 (Avidin-Biotin-Method). The recombinant antigens have been purified by HPLC and FPLC. The products are supplied in lyophilized form and are accompanied by detailed product description as well as by a method sheet.
Swant 的主要产品包括：
（1）Antibodies against Ca2+ - binding proteins
Calbindin
Calretinin
Parvalbumin
Others
（2）Purified and recombinant proteins
Calbindin
Calretinin
Parvalbumin
Others
（3）Antibodies against Ca2+ exchangers and Ca2+ pumps
Ca2+ - exchangers
Ca2+ - pumps
（4）Various
Antibodies against insulin-like growth factors
Antibodies against neurotransmitters
Antibodies against components of the renin-angiotensin system
Miscellaneous antibodies
（5）ELISA KITS
Sandwich-ELISA
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
< " data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Swant"> Swant
invivoCrown IV0103替换BioXCell BE0075-1
invivoCrown IV0115替换BioXCell BE0060
invivoCrown IV0113替换BioXCell BE0075
<艾美捷科技代理Helvetica Health Care品牌全系列产品
Helvetica Health Care是一家位于瑞士日内瓦的医疗保健公司，致力于通过创新的产品和技术来管理健康和提高生活质量。作为瑞士生物技术协会的成员，Helvetica Health Care通过了ISO 13485认证，在质量和创新方面坚持最高标准。涵盖各种质量控制和验证面板，适用于不同的分子测试平台和检测。这些产品有多种规格，可用于单一或多种分析物的检测，帮助实验室监控测试性能，确保测试的准确性和可靠性。其质量控制和验证组合可根据产品配置、填充量和分析物浓度进行定制，满足不同平台的需求。
▎Helvetica Health Care产品线
Helvetica Health Care公司的产品涵盖：抗体、生命科学产品、血液分离产品、临床/诊断样本、质控品与标准品、分子生物学产品、细胞因子与生长因子、ELISA试剂盒/Western印迹相关产品、微生物、氧化应激产品、诊断产品以及人血浆制品。
▎Helvetica Health Care部分产品列表
| 货号 | 产品描述 |
| NATFRC-6C | NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5mL) |
| NATCV9-6C | NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5mL) |
| NATRPC2.1-BIO | NATtrol Respiratory Panel 2.1 (RP2.1) Controls (12 x 0.3mL) |
| NATRVP2.1-BIO | NATtrol Respiratory Verification Panel 2.1 (24 x 0.6mL) (EA) |
| NATRVP2.1-BIO Plus | NATtrol Respiratory Verification Panel 2 Plus (+NATCOV(MR)-BIO) (24x 0.6 ml + 1x 0.6 ml) |
| NATRVP2-QIA | NATtrol Respiratory Verification Panel 2 (21 x 0.25mL) (EA) |
| NATSARS(COV2)-VP | NATtrol SARS-CoV-2 Variant Panel (4 x 0.5mL) |
| NATSARS(COV2)-ERC | SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 0.5 mL) |
| NATSARS(COV2)-ERC1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Positive Control (6x 1.0 ml) |
| NATSARS(COV2)-NEG | SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 0.5 mL) |
| NATSARS(COV2)-NEG1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Negative Control (6x 1.0 ml) |
| NATSARS(COV2)-ST | SARS-Related Coronavirus 2 (SARS-CoV-2) Stock |
| NATSARS(COV2-SA)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock (1mL) |
| NATSARS(COV2-UK)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.1.7 Stock (1mL) |
| 0810229-0.5mg | Coronavirus 229E Lysate (0.5 mg) |
| 0810587 | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (1 mg) |
| 0810587-0.5mg | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (0.5 mg) |
| 0810587CFHI-0.5mL | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (0.5 mL) |
| 0810587CFHI | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (1.0 mL) |
| 0810587UV | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810589CFHI | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810589UV | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (UV Inactivated) (1 mL) |
| 0810590CFHI | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810590UV | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810617UV | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) Culture Fluid (UV)) |
| 0810618UV | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) Culture Fluid (UV) |
| 0810619UV | SARS-CoV-2 Iso1 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810620UV | SARS-CoV-2 Iso2 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810621UV | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) CF (UV Inactivated) |
| 0810622UV | SARS-CoV-2 Lineage B.1.595_2020 (NY-Wadsworth-33126-01/2020) CF (UV Inactivated) |
| 0810612CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:USA/CA_CDC_5574/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810612UV | SARS-CoV-2 Lineage B.1.1.7; Alpha Variant (USA/CA_CDC_5574/2020) CF (UV Inactivated) (1 mL) |
| 0810613CFHI | SARS-CoV-2 Variant B.1.351(Isolate:South_Africa/KRISP-K005325/2020) CF (Heat Inactivated) (1 mL) |
| 0810613UV | SARS-CoV-2 Lineage B.1.351; Beta (South_Africa/KRISP-K005325/2020) CF (UV Inactivated) (1 mL) |
| 0810614CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:England/204820464/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810614UV | SARS-CoV-2 Lineage B.1.1.7 Alpha Variant (England/204820464/2020) CF (UV Inactivated) (1 mL) |
| 0810616CFHI | SARS-CoV-2 Lineage P1; Gamma Variant (Japan/TY7-503/2021) CF (Heat Inactivated) (1 mL) |
| 0810616UV | SARS-CoV-2 Lineage P1; Gamma Variant (Isolate: Japan/TY7-503/2021) CF (UV Inactivated) (1 mL) |
| 0810617CFHI | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) – CFHI (1.0 ml) |
| 0810618CFHI | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) – CFHI (1.0 ml) |
| 0810619CFHI | SARS-CoV-2 Lso1 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810620CFHI | SARS-CoV-2 Lso2 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810621CFHI | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) – CFHI (1.0 ml) |
| 0810622CFHI | SARS-CoV-2 Lineage E3.1.595J2020 (NYWadsworth-33126-01/2020) – CFHI (1.0 ml) |
| 0810623UV | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (UV Inactivated) |
| 0810623CFHI | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (Heat Inactivated) |
| 0810624UV | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (UV Inactivated) |
| 0810624CFHI | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (Heat Inactivated) |
| 0820010CFHI | VeroE6 Culture Fluid (Heat Inactivated) (1 mL) |
| 0801043 | Goat Anti-SARS-CoV-2 Polyclonal Serum (0.5 ml) |
| 0831042 | SARS-CoV-2 (recombinant) Stock (1 x 1.0 mL) |
| 0831043 | SARS-CoV-2 (E/ORF1ab recombinant) Stock (1 x1.0mL) |
| NATSARS-ST | Coronavirus SARS Stock (Qualitative) (1 mL) |
| NATCOV(229E)-ST | Coronavirus 229E Stock (Qualitative) (1 mL) |
| 0810229CFHI | Coronavirus (Strain: 229E) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810229 | Coronavirus Strain: 229E Lysate |
| 0810229UV | Coronavirus (Strain: 229E) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(NL63)-ST | Coronavirus NL63 Stock (Qualitative) (1 mL) |
| 0810228CFHI | Coronavirus (Strain: NL63) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810228 | Coronavirus Strain: NL63 Lysate |
| 0810228UV | Coronavirus (Strain: NL63) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(OC43)-ST | Coronavirus OC43 Stock (Qualitative) (1 mL) |
| 0810024CFHI | Coronavirus (Strain: OC43) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810024 | Coronavirus Strain: OC43 Lysate |
| NATMERS-ST | MERS-CoV Stock (Qualitative) (1 mL) |
| NATMR-BIO | NATtrol MERS Recombinant Pack (2x 0.2 ml +0.5 ml) |
| NATCOV(MR)-BIO | NATtrol MERS-S. Cerevisiae (0.6 ml) |
| 0810575 | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(1mg) |
| 0810575-0.5mg | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(0.5mg) |
| CV033122 | COVID-19 Cross Over Panel (40x 1.0 ml) |
invivoCrown IV0113替换BioXCell BE0075
invivoCrown IV0111替换BioXCell BE0036
invivoCrown IV0101替换BioXCell BE0101
艾美捷科技代理ATTO Biotech全系列产品。
ATTO Biotech专注于开发和提供生命科学研发用的创新产品及服务。公司位于中国上海，主要为全球生物医药类企业及研发机构提供高度专业化的细胞培养材料和技术服务。爱拓生物科技推出的含组织特异性基质成分细胞培养添加剂，突破了传统细胞培养技术的瓶颈，为全球医药和医学生物学研究者提供了简单、精确和高效的解决方案，是划时代技术革命性产品。
ATTO BIOTECH is a German company based inShanghaiChina. We are no giant on an international scale but a global leader in producing cell culture supplements containing tissue-specific decellularized extracellular matrix (ECM) components. Customers choose ATTO BIOTECH for its true research tools of tomorrow to create clinically relevant in vitro solutions that fundamentally change the way we understand human diseases. Our range of highly innovative products has wide applications in life sciences industries and academic institutions.
主要产品包括：
心脏组织特异性细胞外基质添加剂
(Cat# ECM201) heart-specific ECM supplements (hECMs), 10×
动/静脉血管组织特异性细胞外基质添加剂
(Cat# ECM202) artery/vein-specific ECM supplements (aECMs/vECMs), 10×
脑组织特异性细胞外基质添加剂
(Cat# ECM203) brain-specific ECM supplements (bECMs), 10×
胃肠组织特异性细胞外基质添加剂
(Cat# ECM204) gastrointestine-specific ECM supplements (gECMs), 10×
食管组织特异性细胞外基质添加剂
(Cat# ECM205) esophagus-specific ECM supplements (eECMs), 10×
肾胀组织特异性细胞外基质添加剂
(Cat# ECM206) kidney-specific ECM supplements (kECMs), 10×
肝组织特异性细胞外基质添加剂
(Cat# ECM207) liver-specific ECM supplements (liECMs), 10×
脾组织特异性细胞外基质添加剂
(Cat# ECM208) spleen-specific ECM supplements (sECMs), 10×
肺组织特异性细胞外基质添加剂
(Cat# ECM209) lung-specific ECM supplements (luECMs), 10×
气管组织特异性细胞外基质添加剂
(Cat# ECM210) trachea-specific ECM supplements (tECMs), 10×
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="ATTO Biotech"> ATTO Biotech
invivoCrown IV0118替换BioXCell BE0055
地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：17754422825
传真：18771997407
邮箱：sales@amyjet.com
0.1236
